Search
Non-Small Cell Lung Cancer Organoid_main
Cancer Organoid

Non-Small Cell Lung Cancer Organoid

1784€+
Cancer Organoid

Non-Small Cell Lung Cancer Organoid

  • These organoids are useful for studying genetic mutations in lung cancer and testing the efficacy of various chemotherapy treatments.
  • They exhibit protein expression patterns of CK5/6, CK7, P40, and TTF-1, allowing for the distinction between different subtypes of lung cancer.
  • hLC organoids replicate the characteristics of lung cancer tissue.

Price
Organism
Human
Product Type
Organoid
Tissue
Lung alveoli, Bronchi
Disease
Non-Small Cell Lung Cancer

Applications

Oncology

Small Molecule

Antibody

Cancer Vaccine

mRNA

Immune Cell

TME-CAF

Immuno Oncology

Macrophage

Regulatory T Cell

Tumor-Infiltrating Lymphocyte

Cytotoxic T Cell

Professor Lee Chang-seok Eulji University
Customer insight

Advancing K-Beauty with Skin Organoids: A Next-Generation Platform for Non-Animal Testing and High-Precision Cosmetic Innovation

With the global rise of K-beauty, the cosmetics industry continues to grow steadily. Since the ban on animal testing for cosmetics in Korea in 2017, various alternative testing methods have...

Tomocube (Spatial)
Customer insight

HT-X1: A Label-Free Imaging Breakthrough for Organoid-Based Disease Modeling and Drug Screening

Traditional microscopy methods often require fluorescent labeling to analyze cellular structures, which can be time-consuming and invasive. In contrast, our HT-X1 system allows for high-resolution visualization of cellular morphology without...

Seoul National University College of Medicine
Customer insight

Pioneering Spatial Protein Analysis in Korea: Advancing Clinical Pathology with Lambda Biologics’ Support

Traditional protein analysis has primarily focused on quantifying expression levels within tissue samples. However, recent advances in spatial analysis techniques have shifted attention toward evaluating not only expression levels, but...

K Research Institute
Customer insight

ODISEI-Gut Platform Reveals Immune-Boosting Potential of Kimchi-Derived Bacterial Strain

Among the many fermented foods we consume, kimchi is particularly known for containing a diverse range of lactic acid bacteria, which are believed to influence the activation of immune cells...

Bundang Jesaeng General Hospital
Customer insight

Multiplex Marker Analysis Enhances Research Efficiency with 31-Marker Detection on a Single Slide

We conducted a study focused on identifying disease-related markers using patient-derived tissue samples. However, traditional methods limited our ability to analyze multiple candidate markers simultaneously, and the limited availability of...

Description

Table of Contents

Lung cancer organoid

Our lung cancer organoids accurately replicate patient tumors by expressing key markers TTF-1, CK7, p40 and CK5/6, underscoring their fidelity for cancer research and personalized treatment development.

This molecular mimicry enables a profound understanding of lung cancer pathology and offers a promising avenue for therapeutic innovations.
Lung cancer organoid
H&E
TTF-1
CK7
p40 (ΔNp63)
CK5/6

Cancer tissue

Adenocarcinoma

Adenosquamous

Cancer organoid

Adenocarcinoma

Adenosquamous

Genetic mutation

Unlock the essence of precision in cancer treatment with our lung cancer organoids, mirroring the  genetic markers of lung cancer. 
Experience the future of testing you drugs, serving as an invaluable tool in capturing the patient-specific characteristics, thereby providing a more accurate platform for studying tumor biology and testing  Dive into a new era of oncology, where your individuality guides our innovation.
Top mutated genes
Lung cancer mutation PPI Network
Genetic analysis in lung cancer organoids

Utilizing a database of protein interactions and mutations, we statistically analyze genetic correlations to identify significant relationships in lung cancer organoids.

Drug response

Embrace personalized medicine with our cutting-edge platform: Test your drug’s effectiveness against conventional treatments under optimal conditions and discover tailored therapeutic responses. Transform the standard with us—where your medication’s potential is as unique as you are.

Cisplatin

Ctr
1μM
3μM
12μM
50μM

Carboplatin

Ctr
1μM
3μM
12μM
50μM

Gemcitabine

Ctr
0.03μM
0.125μM
0.5μM
2μM

Paclitaxel

Ctr
0.25μM
0.5μM
1μM
20μM

Carboplatin

Cisplatin

Gemcitabine

Paclitaxel

Drug responses of patient-derived lung cancer organoids.
Dose-response curves generated from patient-derived lung cancer organoid lines treated with carboplatin, cisplatin, gemcitabine and paclitaxel.
These figures demonstrate the percent of cell viability measured by celltiter-Glo assay.

Connect with Us